Has Kamal Ramani received payments from drug or device companies?

Yes. Drug and device makers reported $2,554 in general payments to Kamal Ramani across 108 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kamal Ramani did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kamal Ramani come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kamal Ramani

Internal Medicine · New York, NYNPI 1699734996

Payments from drug & device makers

$2,554in general payments, 2019–2025

Across 108 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$348
Lilly USA, LLC$333
Amgen$200
Evofem Biosciences, Inc.$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$131
Merck$112
plus $1K from 25 others

What the payments were for

Food & beverage$2,554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	20	$348
Lilly USA, LLC	7	$333
Amgen	8	$200
Evofem Biosciences, Inc.	7	$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$131
Merck	4	$112
Medtronic	1	$111
Ortho Dermatologics, A Division Of Bausch Health US, LLC	5	$101
Takeda Pharmaceuticals U.S.A., Inc.	4	$94
Therapeuticsmd, Inc.	5	$89
Endo Pharmaceuticals Inc.	4	$77
Lupin Inc.	4	$75
Gilead	2	$64
Pfizer	4	$58
Exact Sciences	2	$56
Bausch Health US, LLC	2	$53
Progenics Pharmaceuticals, Inc.	1	$50
Eisai Inc.	2	$49
Hologic Sales And Service, LLC	2	$47
Shire North American Group Inc	2	$47
AstraZeneca	2	$42
Astellas Pharma US Inc	2	$41
Sebela Pharmaceuticals Inc.	2	$40
Agile Therapeutics, Inc.	2	$38
Biohaven Pharmaceutical Holding Company Ltd.	1	$23
Adlon Therapeutics L.p.	1	$22
Mayne Pharma Commercial LLC	1	$21
Supernus Pharmaceuticals, Inc.	1	$20
Currax Pharmaceuticals LLC	1	$17
Myovant Sciences Inc.	1	$16
Avion Pharmaceuticals	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MOUNJARO$240
INTERSTIM$111

How this compares

$2,554 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Zolpidem Tartrate	31	$286
Rosuvastatin Calcium	20	$159
Atorvastatin Calcium	14	$122
Valsartan	11	$15

Paid to pharmacies, not to this prescriber.

Other internal medicine in New York

Helena YuNew York$50.9M
Neha KordeNew York$21.2M
Karen AutioNew York$18.5M
Ingo MellinghoffNew York$16.1M
Gopakumar IyerNew York$12.4M
Sally LauNew York$8.4M
Maria RubinsteinNew York$6.3M
Dana RathkopfNew York$6M
Eytan SteinNew York$5.8M
James GreenwaldNew York$4.9M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →